6 completed, 4 terminated. 7 Phase 2, 2 Not applicable, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 5, Terminated 2 |
| Not applicable | 2 | Completed 1, Terminated 1 |
| Early Phase 1 | 1 | Terminated 1 |
Follow Stage IVB Oropharyngeal Squamous Cell Carcinoma: new trials by email Literature Review of Stage IVB Oropharyngeal Squamous Cell Carcinoma trials Research Report on Stage IVB Oropharyngeal Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma Cetuximab, Ficlatuzumab - Head and Neck Basaloid Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 2 | Completed | University of Arizona | 78 | 2017-12-05 | 2024-09-04 |
| Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery Paclitaxel, Carboplatin, Nivolumab - Name Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 34 | 2017-11-13 | 2025-04-24 |
| Prepare to Care, A Supported Self-Management Intervention for Head and Neck Cancer CaregiversHead and Neck Cancer Communication Intervention, Watch video, Module completion of the Prepare to Care kit - Caregiver, Malignant Head and Neck Neoplasm | Not applicable | Completed | Wake Forest University Health Sciences | 35 | 2017-05-15 | 2023-01-09 |
| Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer Durvalumab, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery - Human Papillomavirus Infection, Stage I Oral Cavity Squamous Cell Carcinoma | Early Phase 1 | Terminated | Wake Forest University Health Sciences | 17 | 2017-01-01 | 2025-03-17 |
| Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced Head and Neck Cancer Stereotactic Body Radiation Therapy, Positron Emission Tomography, Computed Tomography - Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma | Not applicable | Terminated | Case Comprehensive Cancer Center | 3 | 2015-03-03 | 2019-01-24 |
| Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer Cisplatin, IMRT 6 weeks, IMRT 5 weeks - Stage III Oropharyngeal Squamous Cell Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma | Phase 2 | Completed | NRG Oncology | 316 | 2014-10-01 | 2026-05-22 |
| Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Cisplatin, Laboratory Biomarker Analysis, Pharmacological Study - Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 6 | 2014-03-01 | 2017-05-03 |
| Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer Docetaxel, Hyperfractionation, Intensity-Modulated Radiation Therapy - Human Papillomavirus Infection, Stage I Oropharyngeal Squamous Cell Carcinoma | Phase 2 | Completed | Mayo Clinic | 81 | 2013-09-04 | 2026-02-10 |
| Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer Capecitabine, Vorinostat - Paranasal Sinus Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 25 | 2010-12-01 | 2017-04-14 |
| Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy Cetuximab, Laboratory Biomarker Analysis, Temsirolimus - Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 86 | 2010-11-01 | 2017-03-27 |
Squamous Cell Carcinoma of Head and Neck (10) · Lymphoid Interstitial Pneumonia (4) · Tongue Neoplasms (3) · Head and Neck Neoplasms (2) · Papillomavirus Infections (2) · Carcinoma, Squamous Cell (1) · Lip Neoplasms (1) · Mouth Neoplasms (1) · Oropharyngeal Neoplasms (1) · Salivary Gland Neoplasms (1)
Carcinoma (10) · Neoplasms (10) · Neoplasms by Histologic Type (10) · Neoplasms by Site (10) · Neoplasms, Glandular and Epithelial (10) · Carcinoma, Squamous Cell (9) · Head and Neck Neoplasms (8) · Mouth Diseases (4) · Stomatognathic Diseases (4) · Mouth Neoplasms (3) · Tongue Diseases (3) · Communicable Diseases (2) · DNA Virus Infections (2) · Disease Attributes (2) · Genital Diseases (2)
Cetuximab (2) · Cisplatin (2) · Radiotherapy, Intensity-Modulated (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · Capecitabine (1) · Carboplatin (1) · Disulfides (1) · Docetaxel (1) · Educational Status (1) · Immunoglobulin G (1) · Methods (1) · Nivolumab (1) · Paclitaxel (1) · Platinum (1) · Positron-Emission Tomography (1)
National Cancer Institute (NCI) (3) · Wake Forest University Health Sciences (2) · Case Comprehensive Cancer Center (1) · Mayo Clinic (1) · NRG Oncology (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · University of Arizona (1)
United States (9) · Canada (3) · China (1) · Ireland (1) · Saudi Arabia (1)
Chandylen Nightingale (1) · Daniel Ma (1) · Eric Chen (1) · Eric Winquist (1) · Jennifer Johnson, MD, PhD (1) · Julie E. Bauman, MD, MPH (1) · Mercedes Porosnicu (1) · Shlomo Koyfman (1) · Sue Yom (1) · Tanguy Seiwert (1)
PMID 31163012, PMID 33507809, PMID 35575280, PMID 36977289
N01CM00032 (2), P30CA012197 (2), N01CM00038 (1), N01CM00071 (1), N01CM00099 (1), N01CM62201 (1), P30CA014599 (1), P30CA023074 (1), P30CA043703 (1), R03CA208560 (1), U10CA180868 (1)